Sustained-release opiate blockers for treating heroin and amphetamine dependence

American Journal of Psychiatry

Volumn 169, Issue 5, 2012, Pages 455-457

  Penetar, David M ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALOXONE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO;

ALCOHOL CONSUMPTION; ALCOHOLISM; AMPHETAMINE DEPENDENCE; BOLD SIGNAL; CLINICAL GLOBAL IMPRESSION SCALE; DRUG DEPENDENCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EDITORIAL; GLOBAL ASSESSMENT OF FUNCTIONING SCORE; HEROIN DEPENDENCE; HUMAN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; SUBSTANCE ABUSE; SUSTAINED RELEASE PREPARATION; URINALYSIS; WITHDRAWAL SYNDROME;

EID: 84860499039     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12020210     Document Type: Editorial

References (12)

1. Results from the 2008 National Survey on Drug Use and Health: National Findings: NSDUH Series H-36, HHS Publication SMA 09-4434. Rockville, Md, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2009
2. United Nations Office on Drugs and Crime: World Drug Report 2005. New York, United Nations, 2005
3. Tiihonen J, Krupitsky E, Verbitskaya E, Blokhina E, Mamontova O, Föhr J, Tuomola P, Kuoppasalmi K, Kiviniemi V, Zwartau E: Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 2012; 169:531-536
4. Biggio G, Casu M, Corda MG, Di Bello C, Gessa GL: Stimulation of dopamine synthesis in caudate nucleus by intrastriatal enkephalins and antagonism by naloxone. Science 1978; 200:552-554 (Pubitemid 8328390)
5. Spanagel R, Herz A, Shippenberg TS: Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 1992; 89:2046-2050
6. Carmen B, Angeles M, Ana M, Maria AJ: Efficacy and safety of naltrexone and acomprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99:811-828 (Pubitemid 38869838)
7. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-880
8. Jayaram-Lindström N, Hammarberg A, Beck O, Franck J: Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 2008; 165:1442-1448
9. Jimenez-Gomez C, Winger G, Dean RL, Deaver DR, Woods JH: Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys. Behav Pharmacol 2011; 22:87-90
10. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP: Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63:210-218 (Pubitemid 43213883)
11. Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J: Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 2008; 33:1856-1863 (Pubitemid 351832592)
12. Dunteman GH, Condelli WS, Fairbank JA: Predicting cocaine use among methadone patients: analysis of findings from a national study. Hosp Community Psychiatry 1992; 43:608-611